UNSPSC 51373455: Codeine/potassium citrate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373455 Codeine/potassium citrate, a Commodity code, encompasses pharmaceutical products and controlled substances procured by state and local health and correctional agencies for inpatient and clinical settings. Recent solicitations under this code show state and local governments buying parenteral products including intravenous solutions, parenteral nutrition formulations, and controlled substances for incarcerated populations and community health initiatives. The Washington State Department of Corrections and Seminole County, Florida represent the issuing-body mix — state correctional systems and county health departments — both of which require rapid delivery cycles, stringent insurance and compliance verification, and capability to handle controlled-substance logistics. The Washington DOC opportunity emphasizes delivery within 24 hours for nutrition bags and 8 hours for other parenteral products across three geographic regions of the state; Seminole County's procurement calls for 1,900 units of naloxone annually with quarterly deliveries. Both jurisdictions impose drug-free workplace certification, E-Verify compliance, and specified commercial liability and professional liability insurance as preconditions.

Washington state and Florida are the jurisdictions with documented recent activity. The Washington State Department of Corrections issued RFQQK13020 for parenteral products, services, and equipment on September 8, 2026, with a response deadline of October 7, 2026, and plans to award multiple contractors (up to three per region) with contract terms running November 26, 2026 through June 30, 2030. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, for naloxone and drug deactivation systems with a response deadline of July 26, 2026. Both solicitations include set-aside aspirations and preferences for small, minority-owned, women-owned, and veteran-owned businesses where applicable under state law. Washington DOC's procurement includes pre-bid conference requirements and documentation of subcontractor inclusion plans for disadvantaged enterprises.